文献速递呼吸道感染呼吸危重症与机械通气

PSI与CURB-65评分可良好预测SARS-CoV-2社区获得性肺炎住院患者死亡率

Pneumonia Severity Index and CURB-65 Score Are Good Predictors of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia.
PubMed 文献 · Chest · 2021-11-02

该研究基于美国肯塔基州路易斯维尔八家成人医院的两个前瞻性队列进行二次分析,比较PSI和CURB-65评分对SARS-CoV-2 CAP与非SARS-CoV-2 CAP住院患者院内死亡率的预测效能。结果显示SARS-CoV-2 CAP患者院内死亡率为19%,非SARS-CoV-2 CAP为6.5%;PSI的AUC分别为0.82和0.79,CURB-65的AUC分别为0.79和0.75。在SARS-CoV-2 CAP中,将D-二聚体或降钙素原加入PSI或CURB-65评分对预后效能改善可忽略。

要点

  • PSI和CURB-65评分对SARS-CoV-2 CAP与非SARS-CoV-2 CAP住院患者院内死亡率的预测效能相当。
  • SARS-CoV-2 CAP患者院内死亡率为19%,非SARS-CoV-2 CAP为6.5%。
  • 在SARS-CoV-2 CAP中,将D-二聚体或降钙素原加入PSI或CURB-65评分未改善预后效能。

核心结论

  • PSI和CURB-65评分对SARS-CoV-2 CAP与非SARS-CoV-2 CAP住院患者院内死亡率的预测效能相当。
  • 在SARS-CoV-2 CAP中,将D-二聚体或降钙素原加入PSI或CURB-65评分未改善预后效能。
  • 无论病因如何,PSI和CURB-65评分在临床实践中仍足以预测CAP患者死亡率。

研究设计与样本

  • 研究为对美国肯塔基州路易斯维尔八家成人医院两个前瞻性队列(SARS-CoV-2 CAP或非SARS-CoV-2 CAP患者)的二次分析。

主要发现

  • SARS-CoV-2 CAP患者院内死亡率为19%,非SARS-CoV-2 CAP患者为6.5%。
  • PSI评分在SARS-CoV-2 CAP和非SARS-CoV-2 CAP患者中的AUC分别为0.82(95%CI,0.78-0.86)和0.79(95%CI,0.77-0.80)。
  • CURB-65评分在SARS-CoV-2 CAP和非SARS-CoV-2 CAP患者中的AUC分别为0.79(95%CI,0.75-0.84)和0.75(95%CI,0.73-0.77)。
  • 在SARS-CoV-2 CAP中,将D-二聚体(最佳截断值1,813 μg/mL)和降钙素原(最佳截断值0.19 ng/mL)加入PSI和CURB-65评分对预后效能改善可忽略。

临床怎么用

  • 在临床实践中,无论CAP病因如何,PSI和CURB-65评分仍可用于预测住院患者死亡率。
  • 对于SARS-CoV-2 CAP患者,无需常规将D-二聚体或降钙素原加入PSI或CURB-65评分以改善死亡风险预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Confusion, Urea > 7 mM, Respiratory Rate ≥ 30 breaths/min, BP < 90 mm Hg (Systolic) or < 60 mm Hg (Diastolic), Age ≥ 65 Years (CURB-65) score and the Pneumonia Severity Index (PSI) are well-established clinical prediction rules for predicting mortality in patients hospitalized with community-acquired pneumonia (CAP). SARS-CoV-2 has emerged as a new etiologic agent for CAP, but the role of CURB-65 score and PSI have not been established. RESEARCH QUESTION: How effective are CURB-65 score and PSI at predicting in-hospital mortality resulting from SARS-CoV-2 CAP compared with non-SARS-CoV-2 CAP? Can these clinical prediction rules be optimized to predict mortality in SARS-CoV-2 CAP by addition of procalcitonin and D-dimer? STUDY DESIGN AND METHODS: Secondary analysis of two prospective cohorts of patients with SARS-CoV-2 CAP or non-SARS-CoV-2 CAP from eight adult hospitals in Louisville, Kentucky. RESULTS: The in-hospital mortality rate was 19% for patients with SARS-CoV-2 CAP and 6.5% for patients with non-SARS-CoV-2 CAP. For the PSI score, receiver operating characteristic (ROC) curve analysis resulted in an area under the ROC curve (AUC) of 0.82 (95% CI, 0.78-0.86) and 0.79 (95% CI, 0.77-0.80) for patients with SARS-CoV-2 CAP and non-SARS-CoV-2 CAP, respectively. For the CURB-65 score, ROC analysis resulted in an AUC of 0.79 (95% CI, 0.75-0.84) and 0.75 (95% CI, 0.73-0.77) for patients with SARS-CoV-2 CAP and non-SARS-CoV-2 CAP, respectively. In SARS-CoV-2 CAP, the addition of D-dimer (optimal cutoff, 1,813 μg/mL) and procalcitonin (optimal cutoff, 0.19 ng/mL) to PSI and CURB-65 score provided negligible improvement in prognostic performance. INTERPRETATION: PSI and CURB-65 score can predict in-hospital mortality for patients with SARS-CoV-2 CAP and non-SARS-CoV-2 CAP comparatively. In patients with SARS-CoV-2 CAP, the inclusion of either D-dimer or procalcitonin to PSI or CURB-65 score did not improve the prognostic performance of either score. In patients with CAP, regardless of cause, PSI and CURB-65 score remain adequate for predicting mortality in clinical practice.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Bradley, Sbaih, Chandler, et al. Pneumonia Severity Index and CURB-65 Score Are Good Predictors of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia. Chest. 2021. PMID: 34740594. doi:10.1016/j.chest.2021.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。